In the last sitting of Parliament for 2021, the House of Representatives delivered the long-awaited Zimmerman Report, more formally entitled “The new frontier—delivering better...
Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, was awarded the title of 2021 Partner of the Year...
Date: 25 November 2021Court: Federal Court of AustraliaJudge: Besanko J Background This appeal from a decision of the Australian Patent Office concerned the allowability of...
15 Nov 21 | EU | Celltrion announced that the EC has approved Regkirona® (regdanvimab, CT-P59) for adults with COVID-19 who do not require supplemental oxygen and who are at...
Date: 19 November 2021Court: Full Court of the Federal Court of AustraliaJudges: Middleton, Perram and Nicholas JJ Background In 2018 the Australian Patent Office refused to...
Date: 18 November 2021Court: Federal Court of AustraliaJudge: Burley J Background In December 2016 Pfizer Ireland Pharmaceuticals (Pfizer) filed a preliminary discovery...
The speed of getting a case to trial is a key metric of any litigation system. Pharmaceutical patent litigation often plays out on the cusp of patent expiry when a new market...
09 Nov 21 | Coherus BioSciences reported its Q3 2021 financial results. Coherus announced that FDA review of CHS-201 (proposed adalimumab biosimilar) is advancing towards the...
01 Nov 21 | The International Generic and Biosimilar Medicines Association called on all stakeholders ahead of its second Global Biosimilars Week to join the Biosimilars Movement...
In the last year, two significant Federal Court decisions, reported here and here have exposed key flaws in the Australian Patent Office’s interpretation of the eligibility...
22 Oct 21 | Biocon released its Q2 2022 financial results, reporting a 10% increase in biosimilars revenue year on year. 22 Oct 21 | Chugai Pharmaceutical announced that it will...
14 Oct 21 | Gan & Lee Pharmaceuticals announced the completion of two Ph III studies of its proposed insulin glargine biosimilar. 15 Oct 21 | US | Roche announced that the...
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016, the pharma/biopharma industry finds itself in the Second...
The evolution of jurisprudence in Australia can have far reaching implications for legal practitioners in every jurisdiction. Two recent Federal Court decisions have given...
05 Oct 21 | EU | Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking approval of regdanvimab for the treatment of COVID-19 in...
Date: 20 May 2021 / 18 October 2021Court: Federal Court of AustraliaJudge: Greenwood J Background Australian Patent 2012388708 (Patent) relates to a device and its use in sports...
Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, has been shortlisted as a finalist in the Lawyers...
27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of colorectal,...
October 11 is UN International Day of the Girl Child, a day where we together recognise the unique challenges girls face around the world and seek to advance the rights of girls...
Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement and licence agreement with Pfizer Inc. in relation to MSD’s...
27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million in contingent...
Date: 30 September 2021Court: Federal Court of AustraliaJudge: Rofe J Background The patentee (Surefoot) alleged that seven of the respondents’ (All Footings) products infringe...
18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically meaningful improvement in...
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its BOTOX trade mark and for misleading or deceptive conduct. In...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
